fbpx
QQQ
-1.25
343.51
-0.37%
DIA
-2.67
346.08
-0.78%
SPY
-2.22
426.70
-0.52%
TLT
-0.12
141.17
-0.09%
GLD
-2.96
177.01
-1.7%

Jefferies Comments on Acquisition at Alkermes

by
August 2, 2011 7:07 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Jefferies has published a report on Alkermes (NASDAQ: ALKS) covering a recent acquisition by the biotechnology company.

According to Jefferies, “Alkermes posted a strong quarter with impressive top-line growth. With the EDT transaction to close in September, investor focus will be on a successful integration. A diversified product portfolio should provide cash flow to support development programs that are advancing toward partnership stage. Adjusted EPS beats estimates. For 1QFY12 Alkermes reported an adjusted loss of 0.04
per share. This is a nickel better than our estimate and 8 cents better than consensus. Adjusted earnings excludes $9.5M in costs associated with the EDT merger but does include $5.7M in stock-based compensation.”

Jefferies rated Alkermes a HOLD with a price target of $19.00. Alkermes closed Monday at $16.92.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Your Cheat Sheet For Q1 Biotech Earnings

Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

UPDATE: Jefferies Upgrades Alkermes to Buy

Bank of America has published a report on Alkermes (NASDAQ: ALKS) after a drug court professionals conference.